MedTrace Logo

Effect of Ultra-gyn® on Vulvovaginal Candidiasis

NCT05273333 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-03-10

No results posted yet for this study

Summary

The aim of this post-market clinical follow up study is to confirm the performance and the safety of Ultra-gyn® (when used in accordance with its approved labelling)

Conditions

  • Vulvovaginal Candidiasis, Genital

Interventions

DEVICE

Ultra-gyn®

Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.

Sponsors & Collaborators

  • Biocodex

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-23
Primary Completion
2022-07-31
Completion
2022-12-31

Countries

  • Mauritius

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05273333 on ClinicalTrials.gov